Business Wire

IL-PROJECT44

Share
project44 Buys Last-Mile Delivery and Customer Experience Leader, Convey, in $255M Acquisition

project44, the global leader in real-time supply chain visibility, today announced that it has acquired Austin-based Convey, the last-mile technology leader that powers exceptional direct-to-consumer delivery experiences for more than 200 of the world’s largest brands, including The Home Depot, Nieman Marcus, Ferguson, Ingram-Micro, and others. Convey, recognized as a Challenger in the Gartner 2021 Magic Quadrant for Real-Time Visibility Platforms, combines real-time visibility, post-purchase experiences, and machine learning-powered analytics to improve the overall customer experience. Together, the two companies now serve the global supply chain end-to-end, providing real-time visibility and actionable insights from raw materials to the front door to help brands deliver differentiated direct-to-consumer and eCommerce experiences for their customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005205/en/

The acquisition, for $255 million in total consideration, is project44’s third in 2021 and its largest to date, cementing the company’s position as the connective tissue for modern supply chains. Having achieved unicorn status earlier this year with a valuation of more than $1.2 billion dollars, project44 is the largest visibility platform company as measured by ARR, customer count, and number of carriers. With Convey, project44 now connects more than 880 global shippers and third-party logistics providers with a network of 113,000 carriers, 2.6 million assets and more than 9 billion last-mile shipment events to help shippers optimize costs, grow revenue, improve speed and service and improve the delivery experience.

This acquisition is also significant because it demonstrates project44’s position as the acquirer of choice for Generation 2 logistics technology companies. With three such acquisitions in the past six months, including Ocean Insights, ClearMetal, and now Convey, project44 is the largest Generation 2 logistics technology brand. These modern tech stacks allow project44 to rapidly reuse componentry from the acquired company’s technology within the project44 platform in a dramatically shorter turn-around time than is possible for traditional Generation 1 logistics technology companies.

Once a back-office function, supply chain is now recognized by consumers and the industry as one of - if not the most - critical business function from main street to Wall Street, the world over. According to Gartner®, Inc., “enabling end-to-end supply chain visibility, providing access to customer experience (CX) data and aligning with organization-wide CX structures and initiatives are the top actions being taken to drive a more CX-focused supply chain culture.”1

“project44 is solving today’s most critical business challenge - how to deliver on continuously evolving customer expectations while remaining operationally efficient during unprecedented uncertainty and growing complexity,” said Jett McCandless, CEO and founder of project44. “Our acquisition of Convey brings project44 all the way to the front doorstep and helps our partners become more proactive and efficient so they can get people the products they want and need this holiday and beyond.”

project44 and Convey radically change the way companies view, learn, and react to downstream changes, such as shipping delays, ETA changes, COVID-related worker shortages and port closures. As companies enter a tenuous holiday season, the demand for total order visibility and the ability to get ahead of issues before they occur has never been greater. Added capabilities from Convey, including the ability to resolve parcel delivery issues through automated customer communication, have bolstered project44’s suite of workflow solutions, allowing carriers and logistics service providers to spend less time working manually and more time focused on their core business.

“The stakes are high for companies to not only fulfill and ship orders but to make the right promises about availability and delivery. However, volatile conditions, overwhelming complexity and blind spots in the supply chain make this difficult to achieve,” continued McCandless. “We’ve solved this with the acquisition of Convey, making project44 the unequivocal choice for any company that wants to leverage supply chain and logistics as a competitive advantage and driver of brand loyalty.”

Together, project44 and Convey provide a single solution that delivers value to customers and supply chain partners by:

  • Establishing a unified view of the supply chain - from raw materials to the consumer’s door
  • Providing the same managed and superior consumer delivery experience capabilities in eCommerce to the much larger B2B market
  • Streamlining the day-to-day workflows and collaboration between shippers, sellers and carriers to optimize for reduced overhead and increased time spent on value-added work
  • Expanding the impact of AI on the supply chain through predictive ETAs and dynamic transit times both pre-and-post purchase, powered by the industry’s most trusted, comprehensive, and high-quality transportation dataset

“Salesforce, Google and Adobe have transformed virtually every aspect of the digital customer experience through visibility and intelligent decisioning in the shape of marketing automation, targeted advertising and personalization. Now with Convey, project44 is bringing this approach and cutting-edge technology to the most complex customer experience challenge yet: the supply chain,” said Rob Taylor, founder and CEO of Convey. “We are thrilled to merge forces with project44 and look forward to continuing to build out one of the world’s greatest and most disruptive software companies.”

Improving the Customer Experience

“With thousands of shipments in-flight at any point in time and the details around those orders living in many disparate systems across our organization, it can be difficult to figure out which ones need our immediate attention,” said Devin Van Hout, vice president of digital commerce at Ferguson Enterprises. “Convey’s solution gives our team all the information we need to go from reactive to proactive, while also providing us with the tools to communicate with all relevant parties within the same view. The result is a simple, consistent customer experience in the face of massive B2B complexity.”

project44 will host the first-of-its-kind virtual Supply Chain Live event at 9:00 a.m. CST on September 28. The event will spotlight the challenges facing brands as they approach retail’s busiest season amidst another disruptive year, and feature a fireside chat with Gartner Vice President of Research, Bart De Muynck. To register for Supply Chain Live or to learn more about the key insights from the project44 platform that are critical to retail’s supply chain, visit project44.com .

1 Gartner, “Supply Chain Executive Report Drive Customer Value Through Culture and Insights”: Thomas O'Connor, Beth Coppinger, August 30, 2021. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission.

About project44

project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Air, Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Groupage, Truckload, Rail, Intermodal, and Ocean. In 2021, project44 was named a Leader among Real-Time Transportation Visibility Providers in Gartner’s Magic Quadrant. To learn more, visit www.project44.com .

About Convey

Convey is the global leader in Delivery Experience Management (DEM) and powers exceptional customer delivery experiences for some of the world’s most recognizable brands in retail and logistics. The company’s DEM platform combines estimated delivery date in cart, real-time visibility in-transit, post-purchase communications, and AI-driven insights to create a solution capable of perfecting last mile delivery. Founded in 2013, Convey is based in Austin, Texas. To learn more, visit www.getconvey.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye